Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine plus R-CHOP versus R-CHOP for diffuse large B-cell lymphoma
ChiCTR1900020916Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of decitabine, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Efficacy and Safety. Started Jan 2018; status: recruiting.
02
Drugs
decitabinerituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900020916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020916.